Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long-Term Effects on Serum Immunoglobulins

Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience Over 14 Years

(2017) R. Aguiar et al.   ARTHRITIS CARE & RESEARCH

Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease

(2015) Darren M. Roberts et al.   JOURNAL OF AUTOIMMUNITY

Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus

(2015) Venkat Reddy et al.   Arthritis & Rheumatology

The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease

(2014) Helena Marco et al.   BMC MUSCULOSKELETAL DISORDERS

Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients

(2014) J. Westra et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Serum immunoglobulin G level in patients with lupus nephritis and the effect of treatment with corticosteroids and mycophenolate mofetil

(2014) DYH Yap et al.   LUPUS

Hypogammaglobulinaemia after rituximab treatment--incidence and outcomes

(2014) M. Makatsori et al.   QJM-AN INTERNATIONAL JOURNAL OF MEDICINE

Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis

(2014) Emilio Besada et al.   RHEUMATOLOGY

Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids

(2013) Marie B Condon et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study

(2013) Eduardo F. Mysler et al.   ARTHRITIS AND RHEUMATISM

The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment

(2013) G. Cambridge et al.   JOURNAL OF AUTOIMMUNITY

Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) – results from a nationwide cohort in Germany (GRAID)

(2013) M Witt et al.   LUPUS

Autoantibodies and SLE—the threshold for disease

(2013) Nancy J. Olsen et al.   Nature Reviews Rheumatology

Rituximab-Treated Patients Have a Poor Response to Influenza Vaccination

(2012) Robert A. Eisenberg et al.   JOURNAL OF CLINICAL IMMUNOLOGY

B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells

(2012) Matthieu Mahévas et al.   JOURNAL OF CLINICAL INVESTIGATION

Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics

(2012) Inmaculada De La Torre et al.   RHEUMATOLOGY

Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosus

(2012) Sebastian Eickenberg et al.   ARTHRITIS RESEARCH & THERAPY

Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity

(2012) YK Onno Teng et al.   ARTHRITIS RESEARCH & THERAPY

Meryl Streep and the problems of clinical trials

(2012) David A Isenberg   ARTHRITIS RESEARCH & THERAPY

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial

(2012) Ellen M Ginzler et al.   ARTHRITIS RESEARCH & THERAPY

Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts

(2011) Cándido Díaz-Lagares et al.   AUTOIMMUNITY REVIEWS

Pharmacokinetic Variability of Mycophenolic Acid and Its Glucuronide in Systemic Lupus Erythematosus Patients in Remission Maintenance Phase

(2011) Yasuaki Mino et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase

(2011) Y. Mino et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation

(2011) T. Turner-Stokes et al.   RHEUMATOLOGY

Prevalência de deficiência de IgA em pacientes adultos com lúpus eritematoso sistêmico e estudo de sua associação com perfil clínico e de autoanticorpos

(2011) Ana Paula França Mantovani et al.   Revista Brasileira De Reumatologia

Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab

(2010) H. E. Mei et al.   BLOOD

Decreased frequency and activated phenotype of blood CD27 IgD IgM B lymphocytes is a permanent abnormality in systemic lupus erythematosus patients

(2010) Beatriz Rodríguez-Bayona et al.   ARTHRITIS RESEARCH & THERAPY

Human Marginal Zone B Cells

(2009) Jean-Claude Weill et al.   Annual Review of Immunology

Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus

(2008) D Albert et al.   ANNALS OF THE RHEUMATIC DISEASES

Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma

(2008) L K Hicks et al.   BONE MARROW TRANSPLANTATION